Sexually Transmitted Diseases

BOISE, Idaho, Oct. 30, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Sharon E. Oster, MD, is acknowledged as a Pinnacle Life Member for her contributions to the fields of Internal Medicine and Infectious Diseases. Dr. Oster began her academic journey at the University of Colorado, where she earned a Bachelor of Arts degree with Distinction and was inducted into The Phi Beta Kappa Society. She furthered her education at East Virginia Medical School, where she completed her medical degree in 1980. Recognized as the Resident of the Year, she completed her residency at the Veterans Administration (VA) Medical Center. Dr. Oster has extensive experience prior to her current position, including her work at Saint Alphonsus Hospital from 1999 to 2006. She also served as Chief of the Infection Control Committee in Pinole, CA, from 1990 to 1998. Additionally, she worked with the AIDS clinics in Martinez and Oakland, CA, from 1985 to 1999, and served as an assistant professor of medicine at the University of California, Davis, from 1985 to 1989. A leader in her field, Dr. Oster is considered an expert in internal medicine and infectious diseases. She owns and practices at Oster Medical Group in Boise, ID, and attributes her success to her talent for connecting with her patients. Dedicated to providing the latest innovations in internal medicine and infectious diseases, Dr. Oster is a member of the American Society for Microbiology (ASM), the American Board of Internal Medicine, and her respective state and county medical associations. Her expertise was recognized with America's Best in Medicine Award by the American Health Council in 2019. In addition to her professional pursuits, Dr. Oster volunteers with the Idaho Historical Society and participates as an accomplished flutist in the Canyon County Flute Orchestra and the Mulligan Capital City Band. She also enjoys reading mysteries. Dr. Oster wishes to honor the loving memory of her dear husband, David; her father, Robert; her mother, Caroline; and her grandmother, Ellen Evans. She would also like to acknowledge her daughter, Stephanie, and thank her for her love and support. In the future, Dr. Oster hopes to retire soon. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

A study on point-of-care testing has shown how Syphilis Health Check™ could help significantly improve syphilis screening rates among pregnant patients with limited access to prenatal care, bridging vital gaps between maternal health and STI screening services. STONE HARBOR, N.J., Oct. 30, 2024 /PRNewswire/ -- Diagnostics Direct LLC, a leading provider of diagnostic testing solutions, is pleased to share newly published posters that provide vital insights into the role of rapid testing in improving maternal and neonatal health outcomes. Findings from Dr. Irene Stafford's Preg-OUT program in Southeastern Texas underscore the urgent need for enhanced syphilis detection and treatment in emergency and maternal healthcare settings. A healthcare provider holds a Syphilis Health Check™ test, a rapid diagnostic tool designed for point-of-care syphilis detection.

GSK is setting aside a mid-stage 24-valent pneumococcal vaccine program for adults to instead focus on a preclinical option that covers 30-plus valents, the company announced Wednesday alongside its third-quarter earnings. The decision reflects “increased competition” in the pneumococcal space, a GSK spokesperson told Endpoints News. A 30-valent product for adults would put GSK in rivalry with Vaxcyte’s 31-valent candidate, which read out positive Phase 1/2 results last month. Vaxcyte said at the time that it plans to launch a Phase 3 study in mid-2025. Pfizer, which has also been a fierce competitor in the pneumococcal space, said earlier this week that it has a preclinical 30-plus-valent vaccine in the works. GSK expects to take its 30-plus candidate to the clinic next year, CSO Tony Wood said during a call with investors. The company is still developing a 24-valent candidate for use in children. Elsewhere, GSK culled three other Phase 2 programs, including an anti-CCL17 antibody for osteoarthritis pain, dubbed GSK3858279, and a gonorrhea candidate, called GSK4348413. The spokesperson said an interim Phase 2 analysis for the gonorrhea asset in patients at high risk of infection “did not meet our pre-defined efficacy criteria.” The spokesperson added that there were no safety concerns. The UK pharma also discontinued a Phase 2 program for Herpes simplex virus, GSK3943104, which “did not meet the study’s primary efficacy objective” in the Phase 2 portion of a Phase 1/2 trial. That decision was previously announced in September.